Search
for
Sort by
Research 601–630 of 1000+
- Bullying in persons with skin diseases
- An evaluation of the safety and efficacy of bimatoprost for eyelash growth in pediatric subjects
- Metabolic, Behavioral, and Reproductive Effects of Vertical Sleeve Gastrectomy in an Obese Rat Model of Polycystic Ovary Syndrome
- Long‐term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO‐LT phase 3, open‐label study
- The role of dermocosmetics in the management of cancer-related skin toxicities: international expert consensus
- Health‐related quality of life (hrQoL) among patients with primary cicatricial alopecia (PCA): A systematic review
- Multisystem Inflammatory Syndrome in Adults (MIS-A) and SARS-CoV2: An Evolving Relationship
- ABCD1 Gene Mutations: Mechanisms and Management of Adrenomyeloneuropathy
- Prophylaxis and Management of Skin Toxicities
- Baricitinib for the treatment of severe alopecia areata: results from a 52-week multicenter retrospective real-world study
- Oral minoxidil for late alopecia in cancer survivors
- Circulating Androgen Concentrations and Risk of Incident Heart Failure in Older Men: The Cardiovascular Health Study
- Extracellular Vesicles for Regenerative Medicine Applications
- Therapeutic Effect of Platelet-Rich Plasma Improves Bladder Overactivity in the Pathogenesis of Ketamine-Induced Ulcerative Cystitis in a Rat Model
- Evidence for the efficacy and safety of tadalafil and finasteride in combination for the treatment of lower urinary tract symptoms and erectile dysfunction in men with benign prostatic hyperplasia
- Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies
- Presumptive Albendazole Toxicosis in 12 Alpacas
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme
- Induction of T cell exhaustion by JAK1/3 inhibition in the treatment of alopecia areata
- Association of Spironolactone Use With Risk of Cancer
- The Pressurized Skin: A Review on the Pathological Effect of Mechanical Pressure on the Skin from the Cellular Perspective
- Economic Burden and Healthcare Resource Use of Alopecia Areata in an Insured Population in the USA
- Patient, Oncologist, and Payer Preferences for Adjuvant Endocrine Therapy and CDK4/6 Inhibitor Regimens in Early-Stage Breast Cancer: A Discrete Choice Experiment
- Distribution of Body Hair in Young Australian Women and Associations With Serum Androgen Concentrations
- Hair regrowth in alopecia areata and re‐pigmentation in vitiligo in response to treatment: Commonalities and differences
- The Utility of Monitoring Potassium in Transgender, Gender Diverse, and Nonbinary Individuals on Spironolactone
- Alopecia areata – Current understanding and management
- Epidemiology of Vitiligo – A Dual Population-Based Approach
- Development of the Alopecia Areata Patient Priority Outcomes Instrument: A Qualitative Study
- Patient Preferences: Results of a German Adaptive Choice-Based Conjoint Analysis (Market Research Study Sponsored by Eli Lilly and Company) in Patients on Palliative Treatment for Advanced Breast Cancer